Short Interest in AquaBounty Technologies, Inc. (NASDAQ:AQB) Increases By 90.3%

AquaBounty Technologies, Inc. (NASDAQ:AQB) saw a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 66,398 shares, a growth of 90.3% from the February 26th total of 34,899 shares. Currently, 1.8% of the shares of the stock are short sold. Based on an average daily trading volume, of 27,836 shares, the days-to-cover ratio is presently 2.4 days.

Hedge Funds Weigh In On AquaBounty Technologies

A hedge fund recently bought a new stake in AquaBounty Technologies stock. Two Sigma Investments LP purchased a new position in AquaBounty Technologies, Inc. (NASDAQ:AQB) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 37,565 shares of the company’s stock, valued at approximately $84,000. Two Sigma Investments LP owned 0.97% of AquaBounty Technologies as of its most recent SEC filing. Institutional investors own 8.92% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of AquaBounty Technologies in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, AquaBounty Technologies presently has a consensus rating of “Sell”.

AquaBounty Technologies Trading Up 3.6%

Shares of NASDAQ:AQB opened at $0.94 on Thursday. The company has a 50-day moving average price of $0.94 and a 200-day moving average price of $1.14. The company has a market cap of $3.66 million, a price-to-earnings ratio of -1.14 and a beta of 1.29. AquaBounty Technologies has a 12 month low of $0.60 and a 12 month high of $2.95.

AquaBounty Technologies Company Profile

AquaBounty Technologies, Inc is a biotechnology company focused on aquaculture innovation through the development and commercialization of genetically engineered fish. Its flagship product, AquAdvantage Salmon, is an Atlantic salmon strain enhanced with a growth hormone gene that enables faster growth and more efficient feed conversion compared with conventional farmed salmon. By integrating biotechnology into seafood production, AquaBounty aims to address global protein demand while reducing the environmental footprint associated with marine aquaculture.

Founded in 1991, AquaBounty is headquartered in Maynard, Massachusetts, and operates a state-of-the-art, land-based incubation and grow-out facility in Panama.